{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"101"}]}],"title":"ITP medication at baseline"},{"categories":[{"measurements":[{"groupId":"OG000","value":"71"}]}],"title":"Sustain reduct or stop at least 1 med [1] n=101"},{"categories":[{"measurements":[{"groupId":"OG000","value":"53"}]}],"title":"Permanently stopping at least 1 ITP med [1] n=101"},{"categories":[{"measurements":[{"groupId":"OG000","value":"70"}]}],"title":"Sustained reduction[1] n=101"},{"categories":[{"measurements":[{"groupId":"OG000","value":"66"}]}],"title":"Maximum sustained reduction ≥ 24 weeks[2] n=70"}],"denoms":[{"counts":[{"groupId":"OG000","value":"302"}],"units":"Participants"}],"description":"Sustain reduct: Sustained reduction 1 Denominator is number of subjects taking an ITP medication at baseline. 2 Denominator is number of subjects with a sustained reduction. Note: Sustained reduction defined as reduction from baseline in dose and/or frequency which is maintained for at least 4 weeks. Excludes sustained reductions started more than 1 day after last dose.","groups":[{"description":"Open-label eltrombopag was supplied in 25, 50, 75 mg tablets. All subjects started at 50mg once daily and dose was increased or decreased based on platelet count (target range 50-200Gi/L). Alternate days and interruption of dosing was permitted to maintain target range of platelet count. Doses could range from 25 to 75mg. Subjects could remain on treatment up to 2 years.","id":"OG000","title":"Eltrombopag"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Baseline up to 2 years","title":"Number of Participants With Reduction and/or Sparing of Concomitant ITP Therapies, While Maintaining a Platelet Count ≥ 50,000/mL.","type":"SECONDARY","unitOfMeasure":"Participants"}